<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="anti-feline infectious peritonitis virus (FIPV) properties, we utilized a virtual" exact="screening" post="technique to identify the active site on the viral"/>
 <result pre="peritonitis virus (FIPV) 3CL protease Natural compounds Antiviral activity Virtual" exact="screening" post="Coronavirus 1 Introduction Feline infectious peritonitis (FIP), caused by"/>
 <result pre="dies (Pedersen, 2009). Several strategies have been used for supportive" exact="treatment" post="against this disease. Anti-inflammatory and immunosuppressive drugs have been"/>
 <result pre="of antivirals and immuno-stimulating drugs has been applied for the" exact="treatment" post="of coronaviruses in humans (Pedersen, 2014b). However, there is"/>
 <result pre="databases to generate a library of initial compounds for the" exact="screening" post="process. The structures of the compounds were saved in"/>
 <result pre="and sdf formats prior to the docking analysis. 2.2 Virtual" exact="screening" post="analysis Initial virtual screening studies were carried out using"/>
 <result pre="to the docking analysis. 2.2 Virtual screening analysis Initial virtual" exact="screening" post="studies were carried out using the program AutoDock Vina"/>
 <result pre="5 × 104 cells/well into a 24-well plate for qPCR-based" exact="detection" post="of the virus. The inhibitory activities of each compound"/>
 <result pre="and then washed with PBST buffer. The primary antibody for" exact="detection" post="of FIPV, a mouse monoclonal antibody specific to pan-coronavirus"/>
 <result pre="absolute quantities of viral copy numbers were calculated for each" exact="treatment" post="and control. The antiviral activities of the selected candidate"/>
 <result pre="Antiviral activities of the natural compounds We evaluated the viral" exact="infection" post="based on differential expression of the FIPV antigens within"/>
 <result pre="in CRFK cells during the post-viral entry step of FIPV" exact="infection" post="when FIPV 3CLpro was also expressed by the viral"/>
 <result pre="NSC87511, and NSC343256 could completely protect the cells from virus" exact="infection" post="at concentrations of 20–50 μM. However, the remaining compounds"/>
 <result pre="20–50 μM. However, the remaining compounds could not inhibit FIPV" exact="infection" post="in any of these conditions, despite having good IC50"/>
 <result pre="a positive drug control. Three controls for each compound (FIPV" exact="infection" post="without the compound treatment, FIPV ± Tx; no infection"/>
 <result pre="(FIPV infection without the compound treatment, FIPV ± Tx; no" exact="infection" post="with compound, -FIPV/+Tx; no infection without compound, -FIPV/-Tx) are"/>
 <result pre="treatment, FIPV ± Tx; no infection with compound, -FIPV/+Tx; no" exact="infection" post="without compound, -FIPV/-Tx) are presented on the upper panel."/>
 <result pre="(Omer and Singh, 2017). In our study, the three viral" exact="infection" post="assays showed that chaetochromin could inhibit FIPV infection, with"/>
 <result pre="other antiviral drugs that synergistically inhibit the viruses, rather than" exact="treatment" post="with ribavirin alone, as reported for the MERS-CoV and"/>
 <result pre="It has been used as a reference antiviral compound for" exact="testing" post="the antiviral activities of candidate compounds in several studies."/>
 <result pre="protease, has been commonly used in combination with ritonavir for" exact="treatment" post="of HIV. The booted forms of lopinavir and ritonavir"/>
 <result pre="CID5372747 also inhibited protease activity, but could not control FIPV" exact="infection" post="under all the tested conditions. It is possible that"/>
 <result pre="conclusion, we utilized the application of computer-based assays for virtual" exact="screening" post="to determine potential antiviral candidates for the treatment of"/>
 <result pre="for virtual screening to determine potential antiviral candidates for the" exact="treatment" post="of FIP. We targeted the FIPV 3CLpro, which is"/>
 <result pre="BerryM.FieldingB.C.GamieldienJ.Potential broad spectrum inhibitors of the Coronavirus 3CLpro: a virtual" exact="screening" post="and structure-based drug design studyViruses720156642666026694449 CameronC.E.CastroC.The mechanism of action"/>
 <result pre="cohort studyHong Kong Med. J.9200339940614660806 ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.PeirisJ.S.M.YuenK.Y.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225614985565 DainaA.MichielinO.ZoeteV.SwissADME: a"/>
 <result pre="and medicinal chemistry friendliness of small moleculesSci. Rep.720174271728256516 DallakyanS.OlsonA.J.Small-molecule library" exact="screening" post="by docking with PyRxMethods Mol. Biol.1263201524325025618350 DixitN.M.PerelsonA.S.The metabolism, pharmacokinetics"/>
 <result pre="screen for inhibitors of SARS CoV and its application in" exact="screening" post="of a 100,000-compound libraryJ. Biomol. Screen122007334017200104 SinghS.B.ZinkD.L.BillsG.F.TeranA.SilvermanK.C.LinghamR.B.FelockP.HazudaD.J.Four novel bis-(naphtho-γ-pyrones)"/>
</results>
